News
12-12-2019, 08:09 PM
In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer.
More... (https://www.news-medical.net/news/20191212/Updated-results-from-NRG-OncologyNSABP-B-42-trial-of-extended-letrozole-therapy-for-women-with-HR2b-breast-cancer.aspx)
More... (https://www.news-medical.net/news/20191212/Updated-results-from-NRG-OncologyNSABP-B-42-trial-of-extended-letrozole-therapy-for-women-with-HR2b-breast-cancer.aspx)